Launch of new first-in-class products will push RSV market to $6.3 billion by 2030
The market for respiratory syncytial virus (RSV) prophylaxis is expected to skyrocket from $454.8 million in 2020 to $6.3 billion by 2030 across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, Japan, and Australia), expanding at an impressive compound annual growth rate (CAGR) of 30.1%.
The main driver of growth will be the launch of multiple first-in-class products, according to data and analytics company GlobalData.
GlobalData’s latest report, ‘ Respiratory Syncytial Virus (RSV) Prophylaxis - Global Drug Forecast and Market Analysis to 2030’, reveals that the main driver of growth will be the launch of multiple first-in-class products to prevent medically significant RSV infections, including improved single-dose monoclonal antibodies (MAbs), along with maternal, adult, and pediatric RSV vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze